Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study

Dr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.

Published on August 21, 2017 in Treatment

CPX versus 7 and 3 conventional chemotherapy in older adults with AML

Dr. Stuart Goldberg briefly summarizes updates on CPX-351, a liposomal form of cytarabine and daunorubicin that allows for office infusion vs. standard consolidation requiring hospitalization.

Published on August 7, 2017 in Treatment

Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant IDH2

Dr. Eytan Stein provides a brief update on patients experiencing differentiation syndrome in a larger enasidenib trial, detailing the creation of a Differentiation Syndrome Review Committee.

Published on July 31, 2017 in Treatment

Should all fit, newly diagnosed patients with AML receive 3+7 based induction therapy?

Join Dr. Stone as he explains which patients will benefit the most from 3+7 therapy.

Published on July 24, 2017 in Treatment

How should patients with relapsed mutant FLT3 AML be treated?

In this activity, Dr. Stone will discuss how the midostaurin can be used in the upfront setting for patients with mutant FLT3 AML.

Published on July 17, 2017 in Treatment

What is the emerging role of FLT3 inhibitors in the treatment of newly diagnosed AML?

Join Dr. Stone as he discusses the approval of midostaurin for acute myeloid leukemia, including its use in combination.

Published on July 10, 2017 in Treatment

What are the most exciting new agents in AML and where are they in clinical development?

Dr. Naval Daver discusses the most exciting new agents in acute myeloid leukemia, including their current status in clinical development.

Published on May 31, 2017 in Treatment

Is there data to support routine use of FLT3 inhibitors in AML patients outside of a clinical trial?

Dr. Naval Daver discusses data supporting use of FLT3 inhibitors in patients with AML outside of a clinical trial, including adding midostaurin to standard chemotherapy.

Published on May 31, 2017 in Treatment

What FLT3 inhibitors are being evaluated in AML and what is the development status of these agents?

Join Dr. Naval Daver as he discusses the FLT3 inhibitors that are being evaluated in AML, including quizartinib, gilteritinib, and crenolanib.

Published on May 31, 2017 in Treatment

What are the latest updates on the IDH1 and IDH2 inhibitor studies?

Join Dr. Naval Daver as he reviews the latest data from studies of IDH1 and IDH2 inhibitors, which have shown promising activity in patients with AML.

Published on May 31, 2017 in Treatment